CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 137 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00973973
NCT00973973Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-56418 Sodium in Subjects With Endometriosis

AbbVie·interventional·Posted Sep 9, 2009·Updated Sep 26, 2018

In Brief

A Phase 2 clinical trial evaluating Placebo and Elagolix for Endometriosis, Pain. Completed, enrolled 137 participants.

Detailed Summary

The purpose of this study is to evaluate elagolix (NBI-56418) compared to placebo for its effects on endometriosis related pelvic pain and its safety.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometriosis, Pain
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 9, 2009
Enrollment StartOct 12, 2009
Primary CompletionSep 22, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.8 years ago

Interventions

Placebodrug

Matching placebo tablets taken orally once a day

Elagolixdrug

Immediate release (IR) tablets taken orally once a day